SCHEMBL9627489

SCHEMBL9627489

CCC(C)c1cccc(C)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 2/20 0.38
NFKB1 P19838 2/20 0.38
PNMT P11086 1/20 0.38
LMNA P02545 3/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
SELPLG Q14242 1/20 0.34
RORC P51449 1/20 0.33
P2RX7 Q99572 1/20 0.33
ESR1 P03372 1/20 0.33
S1PR1 P21453 1/20 0.33
MAPK1 P28482 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
SCN4A P35499 3/20 0.32
MAOA P21397 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2632877 0.82 PNMT (0.59) TSHRCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL27391011 0.79 TSHR (0.52) TSHRCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL2737288 0.79 LMNA (0.46) TSHRCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL5496564 0.79 TSHR (0.61) TSHRCYP2D6RORCESR1HTR2A
SCHEMBL793225 0.79 TSHR (0.61) TSHRCYP2D6RORCESR1HTR2A
SCHEMBL5357776 0.79 TSHR (0.61) TSHRCYP2D6RORCESR1HTR2A
SCHEMBL29654913 0.79 TSHR (0.61) TSHRCYP2D6RORCESR1HTR2A
SCHEMBL22871213 0.78 TSHR (0.47) TSHRCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL16957554 0.78 CYP1A2 (0.33) TSHRCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL22969911 0.78 CYP1A2 (0.34) TSHRCYP1A2CYP3A4CYP2D6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10357493-B2 Metalloenzyme inhibitor compounds SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) 2019-07-23 US disclosed
EP-0347690-B1 PROCESS FOR MANUFACTURING BENZENE DERIVATIVES, AND BENZENE DERIVATIVES BASF Aktiengesellschaft (DE) 1992-10-21 EP disclosed
US-5151548-A Crop protection agents BASF AKTIENGESELLSCHAFT (DE) 1992-09-29 US disclosed
EP-0347690-A2 Process for manufacturing benzene derivatives, and benzene derivatives BASF Aktiengesellschaft (DE) 1989-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10357493-B2 Metalloenzyme inhibitor compounds HDAC6, HDAC1, HDAC2 TSHR 3249/4885CYP1A2 3515/4885CYP3A4 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.